Breaking News, Trials & Filings

Basilea’s Antibiotic ZEVTERA Approved for Three Indications

Staphylococcus aureus bloodstream infections, acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company, received approval from the U.S. FDA for ZEVTERA (ceftobiprole medocaril sodium for injection), for the treatment of adult patients with Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis, and adults with acute bacterial skin and skin structure infections (ABSSSI) and for adult and pediatric patients with community-acquired bacterial pneumonia (CABP).   The NDA was supported by clin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters